Cargando…

Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L

Human cytomegalovirus (CMV) utilizes different glycoproteins to enter into fibroblast and epithelial cells. A trimer of glycoproteins H, L, and O (gH/gL/gO) is required for entry into all cells, whereas a pentamer of gH/gL/UL128/UL130/UL131A is selectively required for infection of epithelial, endot...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Li, Taylor, Scott, Costa, Catherine, Görzer, Irene, Kalser, Julia, Fu, Tong-Ming, Freed, Daniel, Wang, Dai, Cui, Xiaohong, Hertel, Laura, McVoy, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323020/
https://www.ncbi.nlm.nih.gov/pubmed/35891489
http://dx.doi.org/10.3390/v14071508
_version_ 1784756447426379776
author He, Li
Taylor, Scott
Costa, Catherine
Görzer, Irene
Kalser, Julia
Fu, Tong-Ming
Freed, Daniel
Wang, Dai
Cui, Xiaohong
Hertel, Laura
McVoy, Michael A.
author_facet He, Li
Taylor, Scott
Costa, Catherine
Görzer, Irene
Kalser, Julia
Fu, Tong-Ming
Freed, Daniel
Wang, Dai
Cui, Xiaohong
Hertel, Laura
McVoy, Michael A.
author_sort He, Li
collection PubMed
description Human cytomegalovirus (CMV) utilizes different glycoproteins to enter into fibroblast and epithelial cells. A trimer of glycoproteins H, L, and O (gH/gL/gO) is required for entry into all cells, whereas a pentamer of gH/gL/UL128/UL130/UL131A is selectively required for infection of epithelial, endothelial, and some myeloid-lineage cells, but not of fibroblasts. Both complexes are of considerable interest for vaccine and immunotherapeutic development but present a conundrum: gH/gL-specific antibodies have moderate potency yet neutralize CMV entry into all cell types, whereas pentamer-specific antibodies are more potent but do not block fibroblast infection. Which cell types and neutralizing activities are important for protective efficacy in vivo remain unclear. Here, we present evidence that certain CMV strains have evolved polymorphisms in gO to evade trimer-specific neutralizing antibodies. Using luciferase-tagged variants of strain TB40/E in which the native gO is replaced by gOs from other strains, we tested the effects of gO polymorphisms on neutralization by monoclonal antibodies (mAbs) targeting four independent epitopes in gH/gL that are common to both trimer and pentamer. Neutralization of fibroblast entry by three mAbs displayed a range of potencies that depended on the gO type, a fourth mAb failed to neutralize fibroblast entry regardless of the gO type, while neutralization of epithelial cell entry by all four mAbs was potent and independent of the gO type. Thus, specific polymorphisms in gO protect the virus from mAb neutralization in the context of fibroblast but not epithelial cell entry. No influence of gO type was observed for protection against CMV hyperimmune globulin or CMV-seropositive human sera, suggesting that antibodies targeting protected gH/gL epitopes represent a minority of the polyclonal neutralizing repertoire induced by natural infection.
format Online
Article
Text
id pubmed-9323020
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93230202022-07-27 Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L He, Li Taylor, Scott Costa, Catherine Görzer, Irene Kalser, Julia Fu, Tong-Ming Freed, Daniel Wang, Dai Cui, Xiaohong Hertel, Laura McVoy, Michael A. Viruses Article Human cytomegalovirus (CMV) utilizes different glycoproteins to enter into fibroblast and epithelial cells. A trimer of glycoproteins H, L, and O (gH/gL/gO) is required for entry into all cells, whereas a pentamer of gH/gL/UL128/UL130/UL131A is selectively required for infection of epithelial, endothelial, and some myeloid-lineage cells, but not of fibroblasts. Both complexes are of considerable interest for vaccine and immunotherapeutic development but present a conundrum: gH/gL-specific antibodies have moderate potency yet neutralize CMV entry into all cell types, whereas pentamer-specific antibodies are more potent but do not block fibroblast infection. Which cell types and neutralizing activities are important for protective efficacy in vivo remain unclear. Here, we present evidence that certain CMV strains have evolved polymorphisms in gO to evade trimer-specific neutralizing antibodies. Using luciferase-tagged variants of strain TB40/E in which the native gO is replaced by gOs from other strains, we tested the effects of gO polymorphisms on neutralization by monoclonal antibodies (mAbs) targeting four independent epitopes in gH/gL that are common to both trimer and pentamer. Neutralization of fibroblast entry by three mAbs displayed a range of potencies that depended on the gO type, a fourth mAb failed to neutralize fibroblast entry regardless of the gO type, while neutralization of epithelial cell entry by all four mAbs was potent and independent of the gO type. Thus, specific polymorphisms in gO protect the virus from mAb neutralization in the context of fibroblast but not epithelial cell entry. No influence of gO type was observed for protection against CMV hyperimmune globulin or CMV-seropositive human sera, suggesting that antibodies targeting protected gH/gL epitopes represent a minority of the polyclonal neutralizing repertoire induced by natural infection. MDPI 2022-07-09 /pmc/articles/PMC9323020/ /pubmed/35891489 http://dx.doi.org/10.3390/v14071508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
He, Li
Taylor, Scott
Costa, Catherine
Görzer, Irene
Kalser, Julia
Fu, Tong-Ming
Freed, Daniel
Wang, Dai
Cui, Xiaohong
Hertel, Laura
McVoy, Michael A.
Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
title Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
title_full Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
title_fullStr Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
title_full_unstemmed Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
title_short Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
title_sort polymorphic forms of human cytomegalovirus glycoprotein o protect against neutralization of fibroblast entry by antibodies targeting epitopes defined by glycoproteins h and l
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323020/
https://www.ncbi.nlm.nih.gov/pubmed/35891489
http://dx.doi.org/10.3390/v14071508
work_keys_str_mv AT heli polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT taylorscott polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT costacatherine polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT gorzerirene polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT kalserjulia polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT futongming polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT freeddaniel polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT wangdai polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT cuixiaohong polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT hertellaura polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl
AT mcvoymichaela polymorphicformsofhumancytomegalovirusglycoproteinoprotectagainstneutralizationoffibroblastentrybyantibodiestargetingepitopesdefinedbyglycoproteinshandl